Navigation Links
Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
Date:5/20/2008

MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: sufficiency of cash resources and our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
2. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
3. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
4. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
11. Neurocrine Biosciences Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Research and Markets has announced ... Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" ... of this report, the human microbiome market is segmented by ... market is expected to be valued as $294 million in ... 22.3% within the forecast period of 2019-2023. The market is ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... LAIYANG, China , May 17 /PRNewswire-Asia-FirstCall/ -- ... pharmaceutical company with its principal operations in the People,s,Republic ... quarter,fiscal year 2010 ended March 31, 2010 . , ... -- Revenue was $25.6 million, a slight decrease of 0.6% ...
... Connecticut waterways may be safer from biomedical waste, thanks to ... CEDF, with loan-program partners, Connecticut ,s Department of Economic and Community and ... to a West Haven company that stems improper disposal of needles ... West Haven ...
Cached Medicine Technology:Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 2Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 3Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 4Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 5Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 6Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 7Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 8Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 9Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 10Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 11Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 12Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 13Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 14Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 15Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 16Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 17Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 18Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 19Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 20Jiangbo Pharmaceuticals Reports Results for Third Quarter of Fiscal Year 2010 21West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund 2
(Date:9/19/2014)... Mozes HealthDay Reporter ... burdened by stress and family conflicts before surgery may ... a new study suggests. Investigators found that patients ... nearly three times greater risk for complications compared to ... "We,ve long known that patient quality of life ...
(Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
(Date:9/19/2014)... CHICAGO --- Domestic violence occurs at least as ... couples compared to opposite-sex couples, according to a ... , Previous studies, when analyzed together, indicate ... percent of lesbian, gay and bisexual individuals. However, ... abuse paints an incomplete picture of the true ...
(Date:9/19/2014)... NY (PRWEB) September 20, 2014 As summer ... Krishnan DMD in Queens, NY now reminds area patients about ... than 80% of our population affected by gum disease, there ... longer.” , For over 20 years Dr. Krishnan has treated ... Hills office location. “Most patients that come in due to ...
(Date:9/19/2014)... 19, 2014) Shahram Majidi, M.D., a second-year ... George Washington University School of Medicine and Health ... Heart Association to study the presence of diffuse ... hemorrhage (ICH). , "According to epidemiological studies, intracerebral ... all strokes, but is the least treatable form ...
Breaking Medicine News(10 mins):Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:A better way to track emerging cell therapies using MRIs 2Health News:Domestic violence likely more frequent for same-sex couples 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2
... Indonesia's resort island of Bali, health officials have culled ... to Bali from the adjacent Java Island, reported Anak ... than 24 bird flu related deaths have been reported ... to the above situation, import of poultry and livestock ...
... by Dr. Martina Stippler it was found that magnesium levels ... A team at the University Of Pittsburgh Brain Trauma Research ... severe brain injuries. The study results were presented at the ... San Francisco. ,The results show that 35 of ...
... demanding the government for new and better breast cancer drugs. ... for Clinical Excellence rejected two new breast cancer drugs for ... groups who were campaigning for access to every new drug ... in clinical trials. The two drugs were docetaxel and paclitaxel. ...
... County Hospital (RHCH) in Winchester, which is already suffering from ... spending ?359,000 caring// for two patients even though they do ... hospital for two years even though they do not need ... since April 2004, the so called "bed blockers", have not ...
... defended the hike in salaries offered to GPs after negative ... claiming //that the wage hikes were responsible for NHS deficits. ... and since then salaries have increased by 25 percent. BMA's ... sensational headlines over the pay being as much as ?100,000 ...
... the cancers that results in death among the Britons. ... a tablet// called Xeloda have only been given to ... Institute of Health and Clinical Excellence (NICE) issued guidance ... who had cancerous tissue removed at an early stage. ...
Cached Medicine News:Health News:Hospitals Facing Huge Losses From Healthy Patients Yet To Discharge 2
...
...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Monitorr ICP external CSF drainage system with self-contained ICP setting....
Medicine Products: